TY - JOUR T1 - Prognosis in Patients With Serous and Mucinous Stage I Borderline Ovarian Tumors JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 770 LP - 777 DO - 10.1097/IGC.0b013e31824b4076 VL - 22 IS - 5 AU - Taejong Song AU - Yoo-Young Lee AU - Chel Hun Choi AU - Tae-Joong Kim AU - Jeong-Won Lee AU - Byoung-Gie Kim AU - Duk-Soo Bae Y1 - 2012/06/01 UR - http://ijgc.bmj.com/content/22/5/770.abstract N2 - Introduction The purpose to this study was to compare the clinicopathologic characteristics and prognosis of patients with serous stage I borderline ovarian tumors (BOTs) to patients with mucinous stage I BOTs.Methods This was a retrospective cohort series of patients with stage I BOTs diagnosed and treated between 1995 and 2009 at a single institution. The records were analyzed for patients’ clinicopathologic information. The recurrence rates were compared using the Kaplan-Meier method.Results During the study period, 198 patients (73.6%) with mucinous BOTs and 71 patients (26.4%) with serous BOTs were identified. Patients with serous tumors tended to be asymptomatic (53.5%) and frequently had elevated CA-125 levels and positive results from peritoneal cytology. Conversely, mucinous tumors were more related to the presence of symptoms (70.7%), elevated CA-19-9 levels, and pseudomyxoma and were larger tumors with a mean size of 15.6 cm. After a median follow-up of 56.5 months, 15 patients had developed 16 recurrences. Among these, 14 borderline recurrences developed in 6 patients with mucinous tumors and in 7 patients with serous tumors, and 2 invasive recurrences developed in only patients with mucinous tumors. No difference in recurrence rate between mucinous and serous tumors was observed. In addition, no disease-related death occurred.Conclusions Our study found that, although distinct differences in clinical and pathologic characteristics between stage I mucinous and serous BOTs are seen, result from tumor histology was not associated with disease prognosis. ER -